Overview

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Status:
RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

Phase:

PHASE3

Details

Lead Sponsor:

Xenon Pharmaceuticals Inc.

Treatments:

XEN1101